European Society of Gene and Cell Therapy
ESGCT is a non-profit scientific society founded in 1992 that promotes gene therapy, cell therapy, and genetic vaccines research across Europe, serving researchers, clinicians, patients, and industry professionals through congresses, education, and publications.
- Company typePrivate
- Founded1992
- HeadquartersBrussels, Belgium
- Headcount1–10
- GTM typeB2B
- OfferingServices
What European Society of Gene and Cell Therapy does
The European Society of Gene and Cell Therapy (ESGCT) is a non-profit scientific society founded in 1992 and headquartered in Brussels, Belgium. It serves as the principal European coordinating body for the research, development, and clinical translation of gene therapy, cell therapy, and genetic vaccines, with a membership spanning researchers, clinicians, patients, industry professionals, and early-career investigators across Europe. Its core product portfolio includes an Annual Congress, a Spring School, an educational Academy, the Human Gene Therapy journal partnership, a Heatmap tool, and various educational resources.
ESGCT generates revenue through three primary streams: individual membership subscriptions priced at €35–€250 per year, event registration fees for its congresses and schools, and industry sponsorships. The society is operationally managed by Lumina Partners Europe (association management firm), uses Shocklogic for event platform services, and has adopted Microsoft 365 with Copilot for internal productivity. It operates primarily across European geographies including the UK, Germany, France, Finland, Greece, Ireland, the Netherlands, Spain, Italy, and Belgium, and maintains structured collaborations with national societies such as BSGCT, DG-GT, and FSGT. ESGCT maintains a lean operational team of 1–10 employees, reflecting its non-profit professional society structure.
European Society of Gene and Cell Therapy firmographics
Firmographics- Name
- European Society of Gene and Cell Therapy
- Legal name
- European Society of Gene and Cell Therapy
- Website
- https://esgct.eu
- Company type
- Private
- Founded year
- 1992
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- ESGCT is a non-profit scientific society founded in 1992 that promotes gene therapy, cell therapy, and genetic vaccines research across Europe, serving researchers, clinicians, patients, and industry professionals through congresses, education, and publications.
- Ownership category
- akta.pro rank
Where European Society of Gene and Cell Therapy is headquartered
LocationHeadquarters
- HQ city
- Brussels
- HQ country
- Belgium
- HQ region
- Europe
Markets served
European Society of Gene and Cell Therapy business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Operations, Personnel, Technology or R&D, Marketing or Sales, Others
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Student membership for enrolled BSc, MSc or PhD students (must provide evidence of student status) |
| Subscription | Annual | Academic membership for researchers and professionals in academia |
| Subscription | Annual | Industry membership for employees of commercial organizations |
| Subscription | Annual | Retired membership for retired professionals in the field |
| Subscription | Annual | Non-Profit membership for employees of registered non-profit organisations (organisation name must be provided and may be verified) |
Distribution channels4 records
Marketing channels8 records
European Society of Gene and Cell Therapy product offering
Product offeringCore offering
ESGCT is a non-profit professional scientific society that promotes basic and clinical research in gene therapy, cell therapy, and genetic vaccines by facilitating education, information exchange, and acting as a professional adviser to EU regulatory bodies. Its core paid offerings include annual membership subscriptions (Student, Academic, Industry, Retired, Non-Profit tiers), flagship events such as the Annual Congress, Spring School, and Academy, free member access to the Human Gene Therapy journal, and corporate sponsorship packages for the Annual Congress.
Product overview
The European Society of Gene and Cell Therapy (ESGCT) is a professional scientific society that does not offer a unified software product but provides a portfolio of membership services, scientific events, educational programs, and publications. The core offerings include the Annual Congress (the 33rd taking place in Hamburg in October 2026), the Spring School (advanced lecture course), the Academy workshop for PhD students, and the Human Gene Therapy Journal. These are complemented by membership benefits, the Gene & Cell Therapy Heatmap database, and public education resources on gene and cell therapy topics.
Differentiator
Problem solved
Functional benefit
Products and services
- ESGCT Annual Congress The ESGCT Annual Congress is the society's flagship annual scientific conference bringing together researchers and clinicians in gene therapy, cell therapy, and genetic vaccines from across Europe and beyond, typically held in October in a major European city. It serves as the primary venue for scientific exchange, abstract presentations, and networking for the European gene and cell therapy community.
- ESGCT Spring School The ESGCT Spring School is an advanced lecture course providing intensive educational programming in gene and cell therapy for researchers and students, typically held in April. It functions as a hands-on training offering for early-career researchers and clinicians in the field.
- ESGCT Academy The ESGCT Academy is an annual workshop where PhD students present their research projects and receive feedback from leading experts in the field, focusing on specific topics in gene and cell therapy. It is targeted at early-career researchers seeking mentorship and visibility.
- Human Gene Therapy Journal Subscription The Human Gene Therapy Journal is a multidisciplinary publication covering all aspects of gene therapy including DNA, RNA, cell and immune therapies, published 12 times per year as the official journal of ESGCT. All ESGCT members receive a free subscription; the journal operates a zero-embargo Green Open Access policy with immediate deposit to PubMed.
- ESGCT Membership ESGCT Membership is an annual subscription product offering access to the Human Gene Therapy journal, Annual Congress discounts, Spring School discounts, travel grants and awards eligibility, networking opportunities, and professional development resources. It is offered in five tiers — Student, Academic, Industry, Retired, and Non-Profit — with annual fees billed on a calendar-year basis.
- Gene & Cell Therapy Heatmap The Gene & Cell Therapy Heatmap is an interactive database showcasing European academic institutions, biotech companies, pharmaceutical industries, charities, and non-profits working in gene and cell therapy to promote awareness and foster collaborations. It is developed by a working group with representatives from European national gene and cell therapy societies.
- Gene & Cell Therapy Education Resources Gene & Cell Therapy Education Resources are educational materials including Gene Therapy 101, COVID-19 vaccine information, vectors basics, cell therapy basics, and clinical trial information for public and patient education. They are freely accessible to the public and intended to support patient and community understanding of advanced therapies.
Companies that use European Society of Gene and Cell Therapy
Customer profileSegments4 records
Ideal customer profiles3 records
European Society of Gene and Cell Therapy technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
European Society of Gene and Cell Therapy partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered core and minor.
- Human Gene Therapy JournalscoreESGCT partners with Human Gene Therapy (HGT) Journals as its official publishing journal for Annual Congress abstracts. All ESGCT members receive a free subscription to the journal (Impact Factor 4.2, 12 double issues per year, average 21 days to first decision). ESGCT shares member profile data with Human Gene Therapy as part of membership acceptance. The journal provides zero-embargo Green Open Access policy and immediate deposit to PubMed.
- DG-GT (Deutsche Gesellschaft für Gentherapie)coreThe 33rd ESGCT Annual Congress (October 2026) is organized in collaboration with DG-GT (German Society for Gene Therapy). The congress will take place at Congress Center Hamburg, Germany, from 27–30 October 2026.
- European National Gene & Cell Therapy SocietiescoreESGCT supports and collaborates with national gene and cell therapy societies across Europe including: BSGCT (UK), DG-GT (Germany), FSGT (Finland), HSGTRM (Greece), ISGCT (Ireland), NVGCT (Netherlands), SFTCG (France), SETGyC (Spain), SITGEC (Italy). ESGCT also references the Gene and Cell Therapy Activity Database (Heatmap) which is developed by a working group with representatives from these national societies.
- Lumina Partners Europe LtdcoreLumina Partners Europe Ltd provides association and event management support to ESGCT. They power the ESGCT website, event registration, membership management, and congress portal infrastructure. ESGCT states that Lumina and relevant sub-contractors may have access to member data as part of contracted services.
- Shocklogic (event and membership management platform)coreESGCT uses the Shocklogic platform for its event and member management system. Member accounts, congress registration, abstract submissions, and congress app functionality are all powered by Shocklogic. Personal data is stored on Shocklogic servers located in the UK and Europe.
- Gene Therapy Center of Excellence Portugal (GeneT / UC)minorThe 9th ESGCT Spring School (April 2026) was jointly organised with the Gene Therapy Center of Excellence Portugal (GeneT) at the University of Coimbra, Portugal. The Spring School took place in Coimbra from 14–17 April 2026.
- T2EVOLVE AssociationminorT2EVOLVE is a newly launched association dedicated to advancing collaboration and innovation in advanced cell therapies across Europe. ESGCT reported on the launch of the T2EVOLVE Association as part of its news coverage, indicating a collaborative or aligned relationship.
- BEYOND MSCA COFUND Program (European Union)minorESGCT promotes the BEYOND Marie Skłodowska-Curie Actions COFUND Postdoctoral Program in Advanced Therapies, co-funded by the European Union. The program recruits 35 postdoctoral fellows for 3-year fellowships at leading European research centres including San Raffaele Telethon Institute for Gene Therapy (Italy), TIGEM (Italy), Lund Stem Cell Center (Sweden), Cambridge Stem Cell Institute (UK), and National Institute of Chemistry (Slovenia). ESGCT shares this opportunity via its Jobs & Courses section.
Recent moves7 records
Expansion highlights5 records
European Society of Gene and Cell Therapy competitors and assessment
Company assessmentEmerging players
- T2EVOLVE Association: Newly launched European association dedicated to advancing collaboration and innovation in advanced cell therapies. Overlaps directly with ESGCT's cell therapy scope and represents an emerging peer that ESGCT already engages with through news coverage.
Direct peers
- European Molecular Biology Organization (EMBO): European life sciences organization funding researchers, running programs, courses, and workshops. Comparable as a European-based scientific community organization serving molecular biology and biomedical research with similar membership/advocacy functions.
- International Society for Stem Cell Research (ISSCR): Global scientific society for stem cell research, with significant overlap on cell therapy, regenerative medicine, and clinical translation. Shares ESGCT's structure of annual meetings, journals, and member-driven research community.
- American Society of Gene & Cell Therapy (ASGCT): The US counterpart professional society for gene and cell therapy. ASGCT runs an annual meeting, advocacy, and member services with nearly identical mission and offerings to ESGCT, making it the most direct comparable peer.
- Deutsche Gesellschaft für Gentherapie (DG-GT): German national society for gene therapy, co-organizing the 2026 ESGCT Annual Congress in Hamburg. Functions as a national-level peer operating the same membership/events/community model in a key European market.
- International Society for Cell & Gene Therapy (ISCT): Global scientific society focused on cell and gene therapy translation, running international conferences, committees, and member programs overlapping directly with ESGCT's mission in cell therapy research and clinical translation.
- British Society for Gene and Cell Therapy (BSGCT): UK national affiliate society for gene and cell therapy; collaborates with ESGCT on UK/European research community building and shares ESGCT's member, event, and journal-based operating model at a national scale.
Others
- European Society for Medical Oncology (ESMO): Large European professional society for oncology professionals. Comparable as a similarly structured European medical society with annual congress, journal, membership tiers, and policy advocacy — adjacent rather than directly competitive to ESGCT.
- European Hematology Association (EHA): European professional society for hematology that overlaps with gene/cell therapy because many advanced therapies target hematologic diseases. Comparable as a European medical society running congresses, journals, and educational programs.
Broad incumbents
- Federation of American Societies for Experimental Biology (FASEB): Umbrella federation of multiple US scientific societies in biological and biomedical research. Comparable as a larger umbrella organization serving multiple member societies with policy advocacy, publications, and conferences.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key highlights6 records
Customer concentration
European Society of Gene and Cell Therapy social profiles
Digital presenceEuropean Society of Gene and Cell Therapy financial estimates
Financial estimateRevenue estimate
Valuation estimate
European Society of Gene and Cell Therapy leadership team
Management profileNumber of profiles
Profiles4 records
European Society of Gene and Cell Therapy funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
European Society of Gene and Cell Therapy M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about European Society of Gene and Cell Therapy
What does European Society of Gene and Cell Therapy do?
ESGCT is a non-profit professional scientific society that promotes basic and clinical research in gene therapy, cell therapy, and genetic vaccines by facilitating education, information exchange, and acting as a professional adviser to EU regulatory bodies. Its core paid offerings include annual membership subscriptions (Student, Academic, Industry, Retired, Non-Profit tiers), flagship events such as the Annual Congress, Spring School, and Academy, free member access to the Human Gene Therapy journal, and corporate sponsorship packages for the Annual Congress.
Is European Society of Gene and Cell Therapy a public or private company?
European Society of Gene and Cell Therapy is a private company. It is classified as nonprofit foundation owned and is currently operating.
When was European Society of Gene and Cell Therapy founded?
European Society of Gene and Cell Therapy was founded in 1992. It employs 1 to 10 people.
Where is European Society of Gene and Cell Therapy based?
European Society of Gene and Cell Therapy is headquartered in Brussels, Belgium, in the Europe region.
Who are European Society of Gene and Cell Therapy's main competitors?
T2EVOLVE Association is listed as an emerging player. Direct peers are European Molecular Biology Organization (EMBO), International Society for Stem Cell Research (ISSCR), American Society of Gene & Cell Therapy (ASGCT), Deutsche Gesellschaft für Gentherapie (DG-GT), International Society for Cell & Gene Therapy (ISCT) and British Society for Gene and Cell Therapy (BSGCT). Others are European Society for Medical Oncology (ESMO) and European Hematology Association (EHA). Federation of American Societies for Experimental Biology (FASEB) is listed as a broad incumbent.
Does European Society of Gene and Cell Therapy have an API?
No public API is recorded for European Society of Gene and Cell Therapy.